The primary objective of the study is to provide continued access to participants who are deriving clinical benefit from ongoing mitapivat treatment in an Agios-sponsored mitapivat study, in the opinion of the Investigator.
This trial phase represents an early or specialized stage of clinical development.
Current status: Enrolling by invitation.
Agios Pharmaceuticals (AGIO) is the sponsoring company for this trial. BiotechSign currently grades this company C (64/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.